ability to differentiate into tumor cells that comprise the bulk of primary tumors and their satellite metastatic tumor nodules. Importantly, CSCs also possess properties associated with de novo and acquired resistance to chemotherapeutics, a trait that imparts significant challenges associated with targeting and killing CSCs (8) . Recent studies suggest that acquired chemotherapeutic resistance of CSCs is a result of epigenetic changes that readily accumulate in these cells when confronted with standard-of-care anticancer agents (14, 15) .
Epigenetic modulation of EMT: Chromatin states prime CSCs for EMT
As mentioned above, carcinoma cells traversing the EMT program lose their epithelial cell polarity and cellcell adhesions and acquire mesenchymal traits, such as the ability to invade and metastasize (1) . While the transcriptomic and phenotypic changes associated with these events have been extensively documented, an emerging area of EMT research focuses on the extrinsic signals that drive the reprogramming of the epigenome. Recent evidence suggests that the tumor microenvironment (TME) signals EMT induction by activating transcription factors associated with EMT [e.g., SNAIL, SLUG, ZEB1, and TWIST (9) ]. Loss of cell-cell adhesions through the inactivation of E-cadherin, a critical adherens junction protein, is a hallmark of the EMT process (9, 16) . Moreover, master EMT transcription factors induced by TME perturbations function to inactivate E-cadherin primary through epigenetic silencing (9) . At present, the means by which epigenomic alterations impact cell fate decisions, including susceptibility to undergo EMT programs, remain to be fully elucidated.
In an attempt address the aforementioned question, Latil and colleagues (17) determined in their recent Cell Stem Cell paper how unique chromatin states in the cancer cell of origin dictate the heterogeneity and behavior of developing squamous cell carcinomas (SCC), as well as their capacity to undergo EMT programs. Previous studies showed that the expression of oncogenic KRas G12D coupled with genetic deletion of p53 deletion in interfollicular epidermal (IEF) cells was sufficient to elicit SCC with well-differentiated morphology; however, recapitulating these same genetic events in hair follicle (HF) cells resulted in SCC bearing multiple morphologies, including well-differentiated SCC, spindle cell SCC, and mixed morphology SCC (18, 19) . Such findings suggest that cell of origin and its unique genetic makeup ultimately determines the tumorigenic fate of distinct cell types to identical genetic events. To test this supposition specifically within IEF and HF epidermal cells, the authors utilized two genetic targeting strategies: (I) the K14-promoter to express CreER preferentially within IFE cells to yield K14CreER/KRas G12D /p53 fl/fl / Rosa-YFP transgenic mice; and (II) the Lrg5-promoter to express CreER preferentially within HF stem cells to yield Lrg5CreER/KRas G12D /p53 fl/fl /Rosa-YFP transgenic mice. In doing so, Latil and colleagues noticed that both K14CreER and Lrg5CreER mice formed tumors that exhibited similar growth and latency rates, typically appearing at ~6-9 weeks of age. Interestingly, K14CreER mice developed almost exclusively well-differentiated SCC that expressed robust levels of epithelial markers, while Lrg5CreER mice developed more numerous tumors with three distinct cellular morphologies: (I) well-differentiated SCC that resembled those of their K14CreER counterparts and contained keratin pearls; (II) mesenchymal SCCs that expressed robust levels of mesenchymal markers; and (III) mixed SCC tumors that represented the most frequently observed SCC tumor and comprised a mixture of well-differentiated and mesenchymal tumor cells. Given the propensity of post-EMT cells to metastasize, Latil and colleagues hypothesized that HF-derived Tumor Mesenchymal Cells (TMCs) would be more likely to form metastases than their IFE-derived Tumor Epithelial Cells (TECs) counterparts. Accordingly, intravenous injection of TMC and TEC derivatives into mice borne out this prediction, suggesting that cancer cell of origin primes tumor cells to undergo EMT and, consequently, dictates their propensity to metastasize.
In an effort to identify the mechanisms whereby EMT priming transpires in the cancer cell of origin, Latil et al. profiled the transcriptomes of both IFE and HF cells, as well as tumors derived from their transformation in the K14CreER and Lrg5CreER mice. Gene set enrichment analysis (GSEA) showed enhanced expression of genes operant in regulating epithelial states in both normal IFE cells, as well as in their TEC Epcam + counterparts. Interestingly, 29% of the genes determined to be upregulated in TEC cells were already expressed robustly in normal IFE cells as compared to HF cells. Amongst the genes coincidently expressed in IFE and TEC cells were the epithelial transcription factors, such as p63, Ovol, Grhl, Cebpa, and Klf5. In stark contrast, GSEA of normal HF and TMC Epcam − cells demonstrated that these cell types were highly enhanced in the expression of EMT-associated genes. As above, 27% of the genes found to be upregulated in TMC cells were highly expressed in normal HF cells. Included amongst the EMT-associated genes coincidently expressed between HF and TMC cells were Ltbp2, Grem1, Flstl1, S100A4, Nfatc1, Tbx1, Tcf4, Tcf7l1, and Ctgf. Collectively, these analyses served to strengthen the notion that basal transcriptional profiles housed within the cancer cell of origin influences the tumorigenicity of their malignant prodigy, as well as their ability to undergo EMT programs.
To extend the aforementioned conclusions, the authors undertook the performance of Assay for Tansposase-Accessible Chromatin sequencing. In doing so, Latil et al. identified how chromatin landscapes change during both tumorigenesis, as well as during EMT programs. As expected, open chromatin regions were identified in genes commonly associated with tumor initiation. Consistent with their transcriptomic profiles analyses described above, Latil and colleagues determined that 139 EMT-responsive genes localized to regions of open chromatin in HF cells, suggesting that epigenetic priming determines cellular propensity to undergo EMT programs. Indeed, TGF-β stimulation of EMT in TMCs readily induced their expression of Jun/AP1, NF1, Ets1, bHLH TGs, Nfatc, and Smad2. Moreover, the authors found that the expression of p63, a gene typically involved in regulating epithelial cell homeostasis, was responsible for suppressing epigenetic and transcriptomic reprogramming coupled to EMT programs in IFE-derived tumors. Along these lines, p63 normally antagonizes oncogenic TGF-β signaling and its stimulation of tumor development and metastatic progression. However, mutant p53 can form a ternary complex with TGF-β-regulated Smads and p63, thereby inactivating the tumor suppressing activities of p63 and enabling the tumor promoting properties of TGF-β, including its stimulation of metastasis and CSC self-renewal (20, 21) .
Taken together, the findings (Figure 1) presented by Latil and colleagues demonstrate how chromatin states within 
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HF genes -Smad2, Tcf7l1, Naftc1 AP1, Klf5, Grhl, Ets, p63, NF1 AP1, Tcf7l1, Nfatc1, Ets, Smad3, NF1 cancer cell of origin dictate carcinoma cell propensity to undergo EMT programs; they also highlight the importance of deciphering the role of epigenetic modifications in driving disease progression and metastasis.
Conclusions and future directions
Mesenchymal-epithelial transitions (MET) represent a reversion to epithelial states following the EMT process; it is also an essential component in the outgrowth and development of secondary metastatic lesions. Indeed, in the absence of continual TME-derived signals, carcinoma cells will readily assume epithelial phenotypes via MET (9) . Thus, it stands to reason that MET programs are equally essential in facilitating metastatic outgrowth by disseminated post-EMT carcinoma cells. It is interesting to note that HFderived TMC metastases appear to be locked into a perpetual EMT state, a condition that has been associated with reduced metastatic competency of SCCs (1, 7, 22) . Thus, future studies need to investigate whether the multiple tumor morphologies noted in HF-derived tumors represent distinct tumor subtypes versus distinct stages of disease progression, as well as the extent to which these events are malleable epigenetically and subject to MET programs.
The gene regulatory network (GRN) developed by Latil and colleagues is hypothesized to predict for EMT programs. As such, Latil et al. investigated the importance of the TGF-β/Smad2 signaling axis in stimulating EMT programs in developing and progressing SCCs. It is interesting to note that the "TGF-β Paradox" was first demonstrated genetically in a mouse model of SCC. Indeed, Cui et al. (23) demonstrated that transgenic expression of TGF-β1 within the epidermis of mice dramatically inhibited carcinogen-induced tumor formation; however, once formed, TGF-β1 rapidly drove the progression and aggressiveness of these spindle cell SCCs, a reaction that coincided with the activation of EMT programs. In the current study, Latil and colleagues focused on the importance of Smad2 in driving SCC progression in response to TGF-β. Teleologically, this is an interesting finding for two reasons. First, EMT programs stimulated by TGF-β commonly reflect its activation of Smad3, not Smad2, and second, Smad2 is incapable of binding to DNA. Thus, future studies need to determine the relative involvement of Smads 3 and 4 in mediating HF/TMCderived tumor development, as well as identify the Smad2interacting proteins responsible for localizing this effector molecule to open chromatin states. Likewise, given the importance of noncanonical TGF-β signaling systems in promoting its oncogenic activity (24) , it therefore seems appropriate to assess the relative contribution of noncanonical TGF-β effectors to epigenetic priming of cancer cell of origin, including their capacity to inactivate the gatekeeper function of p63 (20) .
Finally, CSCs underlie tumor heterogeneity, but the cancer cell of origin appears to give rise to distinct populations of tumors dependent upon their chromatin states and epigenetic priming. This raises the question of how EMT priming by the cancer cell of origin relates to tumor heterogeneity in EMT-dependent tumors, particularly their evolution and progression. As such, future studies should address the importance of epigenetic priming in CSCs, as well as how these chromatin states contribute to the tumorigenicity of CSCs. Ultimately, answering these intriguing questions will build upon this impressive study and will provide the necessary foundation to employ precision medicine approaches against the cancer cell of origin and its unique chromatin state.
